Samer A Srour, MB ChB, MS
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Baylor College of Medicine (tenure track), Houston, TX
Clinical Assistant Professor, The University of Oklahoma Health Sciences Center - Oklahoma City VA Health Care System, Oklahoma City, OK
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, US, Clinical and Translational Science, M.S |
| 2003 | Beirut Arab University, Beirut, LB, Faculty of Medicine, MB CHB |
Postgraduate Training
| 2015-2016 | Clinical Fellowship, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2012 | Clinical Fellowship, Chief Fellow - Hematology/Oncology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma |
| 2009-2012 | Clinical Fellowship, Fellow - Hematology/Oncology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma |
| 2006-2009 | Clinical Residency, Internal Medicine, Staten Island University Hospital, Staten Island, New York |
Licenses & Certifications
| 2015 | Texas State Medical License |
| 2013 | American Board of Internal Medicine - Hematology |
| 2012 | American Board of Internal Medicine - Medical Oncology |
| 2009 | American Board of Internal Medicine - Internal Medicine |
| 2008 | Oklahoma State Medical License |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Assistant Professor, Baylor College of Medicine (tenure track), Houston, TX, 2016 - 2018
Clinical Assistant Professor, The University of Oklahoma Health Sciences Center - Oklahoma City VA Health Care System, Oklahoma City, OK, 2012 - 2015
Extramural Institutional Committee Activities
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Member, Scientific Review Committee #1, The University of Texas MD Anderson Cancer Center, 2019 - Present
Co-Chair, cME Accredited Hematological Malignancies Tumor Board, CHI Baylor St. Luke’s Medical Center, The University of Texas MD Anderson Cancer Center, 2017 - 2018
Oncology Section Representative, Oklahoma City VA Medical Center Cancer Committee,, The University of Texas MD Anderson Cancer Center, 2012 - 2015
Member, Post ASCO Planning Committee - The University of Oklahoma Health Sciences Center, The University of Texas MD Anderson Cancer Center, 2012
Member, Resident Council - The University of Oklahoma Health Sciences Center, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Honors & Awards
| 2016 | Conquer Cancer Foundation Merit Award, Conquer Cancer Foundation |
| 2014 | Travel Award, American Federation for Medical Research |
| 2012 | Travel Award, American Federation for Medical Research |
| 2011 | Trainee Travel Award, American Society of Clinical Oncology |
| 2008 | Excellence Award for Patient Care, Staten Island University Hospital |
| 2007 | Certificate of Achievement for Participation and Distinguished Achievement in Medical Research and Scholarly Activity, Staten Island University Hospital, |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Orca-T Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
National Presentations
- 2025. Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress. Poster. ASCO Annual Meeting. Chicago, IL, US.
- 2025. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study. Conference. ASCO Annual Meeting. Chicago, IL, US.
- 2025. Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress. Poster. AACR Annual Meeting. Chicago, IL, US.
- 2025. ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the phase 1 dose escalation study. Conference. AACR Annual Meeting. Chicago, IL, US.
- 2025. ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated safety and efficacy from the phase 1 TRAVERSE multicenter study. Conference. SITC Annual Meeting. San Diego, CA, US.
- 2025. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Conference. ASTCT Annual Meeting. Honolulu, HI, US.
- 2024. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Poster. ASH Annual Meeting. San Diego, CA, US.
- 2024. Targeting CD70 in RCC using cellular therapy. Invited. 2024 Global Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
- 2024. The rationale for CAR-T targeting carbonic anhydrase 9 as a therapeutic approach for RCC. Invited. 2024 Global Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
- 2024. Re-engineering the immune system to treat cancer. Invited. 27th International Thyroid Cancer Survivors’ Conference. Houston, TX, US.
- 2024. Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study. Poster. ASCO Annual Meeting. Chicago, IL, US.
- 2024. CT002 - CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study. Conference. AACR Annual Meeting. San Diego, CA, US.
- 2023. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas. Conference. ASH Annual Meeting. San Diego, CA, US.
- 2023. Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide. Conference. ASH Annual Meeting. San Diego, CA, US.
- 2023. Logistics of Cell Therapy Delivery. Invited. AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. Arlington, VA, US.
- 2023. Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers. Poster. ASCO Annual Meeting. Chicago, IL, US.
- 2023. Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma. Conference. AACR Annual Meeting. Orlando, FL, US.
- 2023. Orca-Q demonstrates favorable GvHD-and-relapse-free survival with haploidentical donors without post-transplant cyclophosphamide. Conference. Tandem Meetings of ASTCT and CIBMTR. Orlando, FL, US.
- 2022. Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies. Conference. SOHO Annual Meeting. Houston, TX, US.
- 2022. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). Poster. ASCO Annual Meeting. Chicago, IL, US.
- 2019. Melphalan dose intensity for autologous stem cell transplantation (ASCT) in multiple myeloma. Conference. TCT Annual Meetings. Houston, TX, US.
- 2018. Immunosuppression Withdrawal is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. Conference. 2018 BMT Tandem Meetings. Salt Lake City, UT, US.
- 2017. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Conference. 2017 American Society of Hematology (ASH) Annual Meeting. Atlanta, GA, US.
- 2016. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Conference. American Society of Hematology (ASH) Annual Meeting. San Diego, CA, US.
- 2016. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Conference. 2016 American Society of Hematology (ASH) Annual Meeting. San Diego, CA, US.
- 2016. Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide: A Single Institution Experience. Conference. BMT TANDEM. Honolulu, HI, US.
- 2015. Analysis of Outcome of Patients with Acute Myeloid Leukemia According to Socio-Economic Status. Conference. American Society of Hematology (ASH) Annual Meeting. Orlando, FL, US.
- 2015. Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era. Conference. American Society of Hematology (ASH) Annual Meeting. Orlando, FL, US.
- 2013. Acute Myeloid Leukemia: Pretreatment Biochemical and Clinical Variables Predictive For Risk Status Based On Validated Cytogenetic and Molecular Abnormalities. Conference. American Society of Hematology (ASH) Annual Meeting. New Orleans, LA, US.
- 2013. Erlotinib is Not Effective in Patients (Pts) with JAK-2 V617F Positive Polycythemia Vera. Conference. American Society of Hematology (ASH) Annual Meeting. New Orleans, LA, US.
International Presentations
- 2023. Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers. Invited. ASCO Annual Meeting. Chicago, US.
- 2022. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). Conference. ASCO Annual Meeting. Chicago, US.
- 2016. High-Dose versus Standard-Dose Rituximab with BEAM in Autologous Stem Cell Transplantation (SCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHL). Conference. 2016 European Hematology Association Congress Meeting - Abstract P342. Copenhagen, DK.
- 2016. High-Dose versus Standard-Dose Rituximab with BEAM in Autologous Stem Cell Transplantation (SCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHLs). Conference. 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
- 2016. Pemetrexed in Combination with Cisplatin versus Carboplatin as First-line Therapy in Patients with Advanced-Stage Malignant Pleural Mesothelioma (MPM): A Systematic Review and Meta-analysis. Conference. American Society of Clinical Oncology (ASCO). Chicago, US.
- 2013. Acute Myeloid leukemia: Comparison of Epidemiology and Treatment Outcomes between Insured and Uninsured Patients. Conference. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
- 2012. Acute Myeloid leukemia: Comparison of Epidemiology and Treatment Outcomes between Insured and Uninsured Patients. Conference. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
- 2011. Role of Topotecan, Vinorelbine, Thiotepa, and Gemcitabine (TVTG) Chemotheapy in Relapsed/refractory Adult Acute Leukemia: A Single-Institution Retrospective Analysis. Conference. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
Formal Peers
- 2016. Management of Cancer-Associated Venous Thromboembolism. Invited. Houston, TX, US.
- 2016. Frontline Treatment for Mantle Cell Lymphoma: the Past and the Future. Invited. Mineola, NY, US.
- 2012. Blood Cancers: Acute Leukemias. Invited. Stroud, OK, US.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Title: Effect of SIRP alpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched related donor |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Date: | 2023 - 2030 |
| Title: | A Long-term Follow-up Study of Subjects with Malignancies Treated With CRISPR CAR Cellular Therapies |
| Funding Source: | CRISPR Therapeutics |
| Role: | PI |
| ID: | 00062919 |
| Date: | 2023 - 2030 |
| Title: | Title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors |
| Funding Source: | CRISPR Therapeutics |
| Role: | PI |
| ID: | 7418/ 00015128 |
| Date: | 2023 - 2030 |
| Title: | Title: 2022-0466 An Open-Label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients with Platinum-Resistant Epithelial Ovarian Cancer |
| Funding Source: | ArsenaBio |
| Role: | PI |
| ID: | 7128/ 00014729 |
| Date: | 2022 - 2029 |
| Title: | : Phase 1 Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Newly Diagnosed Anaplastic Thyroid Cancer |
| Funding Source: | AffyImmune therapeautics |
| Role: | PI |
| ID: | 6676/00014030 |
| Date: | 2021 - 2025 |
| Title: | SIV: STRATEGIC Alliance Agreement- A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Allogene Therapeutics |
| Funding Source: | Allogene Therapeutics |
| Role: | PI |
| ID: | 59539/000012676 |
| Date: | 2021 - 2028 |
| Title: | A Phase 1, Dose Escalation and Dose Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orca-Q), with Single-Agent Graft-versus-Host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies |
| Funding Source: | Orca Biosystems, Inc |
| Role: | PI |
| ID: | 5493/00012447 |
| Date: | 2020 - 2027 |
| Title: | A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9– Engineered T Cells (CTX130) in Adult Subjects with Advanced, Relapsed or Refractory Renal Cell Carcinoma (RCC) with Clear Cell Differentiation |
| Funding Source: | CRISPR Therapeutics |
| Role: | PI |
| ID: | 00012039 |
| Date: | 2020 - 2027 |
| Title: | A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with TregGraft, a T‐cell‐Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells |
| Funding Source: | Orca Biosystems, Inc |
| Role: | PI |
| ID: | 5236/00012067 |
| Date: | 2012 - 2022 |
| Title: | Phase II study of umbilical cord blood-derived natural killer cells in conjunction with elotuzumab, lenalidomide and high dose melphalan followed by autologous stem cell transplant for patients with multiple myeloma |
| Funding Source: | Celgene |
| Role: | PI |
| ID: | CV36486 |
Selected Publications
Peer-Reviewed Articles
- Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
- Saliba, RM, Niemann, M, Srour, S, Greenbaum, U, Alzahrani, K, Carmazzi, Y, Rondon, G, Rezvani, K, Daher, M, Li, D, Ma, Q, Tanner, MR, Cao, K, Shpall, E, Champlin, RE, Spierings, E, Zou, J. Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants. Transplantation and Cellular Therapy 31(11):903-915, 2025. e-Pub 2025. PMID: 40714365.
- Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
- Lee, SJ, Logan, BR, Horowitz, MM, Dehn, J, Pidala, J, Grunwald, MR, Westervelt, P, Farhadfar, N, Hogan, WJ, Bashey, A, Hayes-Lattin, BM, Hill, LQ, Brunstein, C, Arai, S, Srour, S, Symons, H, Uberti, JP, Vasu, S, Pusic, I, Juckett, M, Leifer, ES, He, N, Devine, S, Shaw, BE, Ciurea, SO. Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702. Journal of Clinical Oncology 30, 2025. e-Pub 2025. PMID: 40966481.
- Pasvolsky, O, Marcoux, C, Milton, D, Rafaeli, N, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Mohamedi, A, Deen, AF, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplantation and Cellular Therapy 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
- Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
- Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
- Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
- Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
- Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
- Ramdial, JL, Lin, R, Thall, PF, Valdez, B, Hosing, C, Srour, S, Popat, U, Qazilbash, MH, Alousi, AM, Barnett, M, Gulbis, A, Shigle, TL, Shpall, EJ, Andersson, BS, Nieto, Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone marrow transplantation 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
- Kongtim, P, Vittayawacharin, P, Zou, J, Srour, S, Shaffer, BC, Shapiro, R, Varma, A, McGuirk, J, Dholaria, B, McCurdy, SR, Dezern, A, Bejanyan, N, Bashey, A, Fürst, S, Castagna, L, Mariotti, J, Ruggeri, A, Bailen, R, Teshima, T, Xiao-Jun, H, Bonfim, C, Aung, FM, Cao, K, Carpenter, P, Hamadani, M, Askar, M, Fernandez-Vina, M, Girnita, A, Ciurea, SO. ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transplantation and Cellular Therapy 30(12):1139-1154, 2024. e-Pub 2024. PMID: 39260570.
- Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
- Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
- Pal SK, Tran B, JBAG H, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov 14(7):1176-1189, 2024. e-Pub 2024. PMID: 38583184.
- Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, Chen J, Rondon G, Olson A, Im J, Hosing C, Shpall E, Champlin R, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
- Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
- Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
- Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
- Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
- Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
- Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DA. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol 99(5):890-899, 2024. e-Pub 2024. PMID: 38444268.
- Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
- Nieto Y, Yang Z, Valdez BC, Kundu S, Bashir Q, Ramdial J, Srour S, Qazilbash M. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol 99(2):245-253, 2024. e-Pub 2024. PMID: 38100199.
- Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING AUTOLOGOUS CELL TRANSPLANTATION. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
- Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther 30(2):203.e1-203.e9, 2024. e-Pub 2024. PMID: 38042257.
- Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
- Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
- Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
- Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
- Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
- Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
- Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
- Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
- Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged = 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
- Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
- Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
- Wang XS, Srour SA, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, Kamal M, Shen SE, Cleeland C, Kebriaei P, Rezvani K, Neelapu S, Ahmed S, Shpall E. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol 201(4):738-746, 2023. e-Pub 2023. PMID: 36733986.
- Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
- Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
- Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
- Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
- Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
- Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
- Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
- Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
- Saengboon, S, Ramdial, JL, Saini, N, Olson, AL, Im, J, Hosing, C, Popat, UR, Shpall, E, Champlin, RE, Srour, S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S259-S260, 2022. e-Pub 2022. PMID: 36163857.
- Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
- Meyer, E, Pavlova, A, Gandhi, A, Hoeg, R, Oliai, C, Mehta, RS, Srour, S, McGuirk, J, Waller, EK, Fernhoff, N, Killian, MS, Mcclellan, J, Putnam, A, Shaw, BE, Abedi, M, Negrin, R. CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S447, 2022. e-Pub 2022. PMID: 36164225.
- Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
- Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
- Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
- Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
- Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
- Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
- Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
- Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica 107(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
- Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
- Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):710-721, 2022. e-Pub 2022. PMID: 34686083.
- Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
- Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol 13:1033871, 2022. e-Pub 2022. PMID: 36311784.
- Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol 13:904718, 2022. e-Pub 2022. PMID: 35874659.
- Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
- Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
- Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, Kebriaei P, Neelapu SS, Shpall E, Ahmed S, Wang XS. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol Nurs 37(6):151216, 2021. e-Pub 2021. PMID: 34629213.
- Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
- Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
- Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P, Neelapu SS, Rezvani K, Ahmed S, Shpall E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
- Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
- Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
- Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
- Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
- Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
- Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
- Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
- Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
- Srour, S, Saliba, RM, Bashir, Q, Popat, UR, Ahmed, S, Mehta, RS, Delgado, R, Rondon, G, Parmar, S, Kebriaei, P, Hosing, C, Manasanch, EE, Lee, HC, Patel, K, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Nieto, Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
- Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):278-281, 2021. e-Pub 2021. PMID: 32636464.
- Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):74-81, 2021. e-Pub 2021. PMID: 32604096.
- Srour SA, Popat UR. Impact of Mixed Chimerism on Myelofibrosis Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(12):e301-e302, 2020. e-Pub 2020. PMID: 32949752.
- Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
- Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, Srour S, Partlow D, Champlin RE, Cao K. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv 4(15):3474-3485, 2020. e-Pub 2020. PMID: 32726398.
- Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
- Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32602112.
- Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE, Ciurea SO, Saliba RM. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(5):1013-1020, 2020. e-Pub 2020. PMID: 32045652.
- Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
- Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
- Srour SA, Qazilbash MH. Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation. Ann Transl Med 8(7):509, 2020. e-Pub 2020. PMID: 32395553.
- Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
- Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
- Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
- Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
- Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31518645.
- Saini NY, Ma J, Milton DR, Patel RD, Varma A, Bashir Q, Delgado RE, Tang G, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi A, Ahmed S, Mehta R, Srour S, Khouri IF, Iyer S, Weber D, Thomas SK, Lee HC, Manasanch EE, Patel K, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res. e-Pub 2019. PMID: 31481508.
- Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
- van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv 3(12):1858-1867, 2019. e-Pub 2019. PMID: 31217161.
- Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
- Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. e-Pub 2019. PMID: 30948491.
- Popat UR, Mehta RS, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi A, Anderlini P, A-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson AO, Oran B, Parmar S, Rezvani K, Qasilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematology 5:532-42, 2018. e-Pub 2018. PMID: 30389035.
- Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
- Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang ML. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. Br J Haematol 181(4):561-564, 2018. e-Pub 2018. PMID: 28369820.
- Ibrahimi S, Mukherjee S, Machiorlatti MG, Maymani H, Vesely SK, Srour SA, Cherry M. Effect of time of admission to treatment initiation on outcomes of patients with acute myeloid leukemia: a tertiary care referral center experience. J Community Support Oncol 16(5):e188-e93, 2018. e-Pub 2018.
- Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
- Srour SA, Machiorlatti M, Pierson NT, Bhutta UZ, Cherry M, Selby GB, Thompson DM, Vesely SK, Kurkjian CD. Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 17(7):450-456.e2, 2017. e-Pub 2017. PMID: 28624543.
- Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
- Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(2):318-324, 2017. e-Pub 2017. PMID: 27856368.
- Wu ES, Srour SA. Paraneoplastic hyperleukocytosis in pancreatic andenocarcinoma. Journal of Pancreatic Cancer 3(1):84-86, 2017. e-Pub 2017.
- George S, Gehrs BC, Srour SA. Primary cardiac prosthetic valve-associated lymphoma: a case report and review of literature. J Community Support Oncol 15(2):109-12, 2017. e-Pub 2017.
- Srour SA Shaoying L, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of high-dose versus standard-dose rituximab with beam in autologous stem cell transplantation for relapsed aggressive b-cell non-hodgkin’s lymphomas: long term results. Br J Haematol 178(4):561-70, 2017. e-Pub 2017.
- Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
- Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
- Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, Dores GM. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol 174(3):382-96, 2016. e-Pub 2016. PMID: 27061824.
- Gaballa S, Saliba R, Srour SA, Lu G, Brammer J, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah J, Manasanch E, Orlowski R, Champlin R, Qazilbash M. Outcomes of multiple myeloma patients with TP53 deletion after autologous hematopoietic stem cell transplantation. Am J Hematol 22(12):2159-64, 2016. e-Pub 2016.
- Cherry M, Khawandanah M, Zhao ZJ, Srour S, Ozer H, Selby G, Ghabache B, Al-Kali A. Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol 94(4):717-9, 2015. e-Pub 2015. PMID: 25380996.
- Srour SA, Borders EB, Cherry MA, Holter J, Herman T, Selby GB. Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia. Leuk Lymphoma 56(10):2962-4, 2015. e-Pub 2015. PMID: 25721752.
- Srour SA, Workman M, Yang JT, Abdullah SA, Cherry MA. An unusual presentation of an aggressive spindle cell skin cancer. J Community Support Oncol 12(4):149-52, 2014. e-Pub 2014. PMID: 24971424.
- Cherry MA, Bhardwaj H, Hopps S, Srour S, Pant S. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. J Oncol Pharm Pract 19(3):261-4, 2013. e-Pub 2013. PMID: 23135805.
- Kurdgelashvili G, Dores GM, Srour SA, Chaturvedi AK, Huycke MM, Devesa SS. Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007. Cancer 119(12):2291-9, 2013. e-Pub 2013. PMID: 23580435.
- Cherry, MA, Srour SA, Kern W, Al-Kali A. Bone marrow fibrosis reversal after use of hydroxyurea in a patient with myelofibrosis. Commun Oncol 102(2):58-61, 2013. e-Pub 2013.
- Srour SA, Goldberg E, Najjar S. Paraneoplastic myelitis related to diffuse large b-cell lymphoma and hodgkin’s lymphoma: two case reports and literature review. Commun Oncol 7(7):323-26, 2010. e-Pub 2010.
Review Articles
- Wang, XS, Srour, S. Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies. Hematology (United States) 2024(1):102-108, 2024. e-Pub 2024. PMID: 39644035.
- Srour SA, Akin S. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. J Immunother Precis Oncol 6(1):19-30, 2023. e-Pub 2023. PMID: 36751657.
- Beitinjaneh A, Kaufman A, Wang Y, Jain P, Srour SA, Wang M. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?. Curr Treat Options Oncol 23(11):1614-1625, 2022. e-Pub 2022. PMID: 36227407.
- Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric antigen receptor T-cell therapy toxicities. Br J Clin Pharmacol 87(6):2414-2424, 2021. e-Pub 2021. PMID: 32463929.
- Kamal M, Joseph J, Greenbaum U, Hicklen R, Kebriaei P, Srour SA, Wang XS. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplant Cell Ther 27(5):390.e1-390.e7, 2021. e-Pub 2021. PMID: 33965176.
- Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
Abstracts
- Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2019. PMID: 31296578.
- Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, MOlldrem JJ, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial, 2019. e-Pub 2019.
- Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, CIurea SO, Qazilbash MH, rezvani K, Shpall EJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant, 2019. e-Pub 2019.
- Srour SA, Desai PA, Ciurea SO, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Alousi AM, Verstovsek S, Champlin RE, and Popat RU. Immunosuppression Withdrawal is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant(24):S119 - S290, 2018. e-Pub 2018.
- Srour SA, Desai P, Ciurea S, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta R, Pemmaraju N, Verstovsek S, Champlin RE, and Popat UR. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130(2007), 2017. e-Pub 2017.
- Srour, SA, Saliba, R M, Delgado, R, Qazilbash, M H, Bashir, Q, Shah, N, Popat, U R, Ahmed, S, Patel, K, Jones, R, Rondon, G, Champlin, R E, Nieto, Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Blood 128(22):3314, 2016. e-Pub 2016.
- Srour SA, Khouri IF, Lozano-Cerrada S, Nieto Y, Alousi AM, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall E, Champlin RE, and Hosing C. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Blood(128):2270, 2016. e-Pub 2016.
- Srour SA, Khouri IF, Nieto Y, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall E, Champlin RE, and Hosing C. High-Dose versus Standard-Dose Rituximab with BEAM in Autologous Stem Cell Transplantation (SCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHLs). J Clin Oncol 34(15):S7524, 2016. e-Pub 2016.
- Ramlal R, Sasaki K, Lozano Cerrada S, Srour SA, Chen J, Rondon G, Rezvani K, Oran B, Olson A, Shpall EJ, Champlin RE, and Ciurea SO. Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide: A Single Institution Experience. Biol Blood Marrow Transplant(22):s375-76, 2016. e-Pub 2016.
- Srour SA, Stoner, JA. Pemetrexed in Combination with Cisplatin versus Carboplatin as First-line Therapy in Patients with Advanced-Stage Malignant Pleural Mesothelioma (MPM): A Systematic Review and Meta-analysis. J Clin Oncol 34(14):s8554, 2016. e-Pub 2016.
- Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, and Dores GM. Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era. Blood(126):2806, 2015. e-Pub 2015.
- Pierson P, Chaudry S, Vidal G, Machiorlatti M, Frank S, Vesely SK, Feisal JK, Srour SA, Khalil MO, Ikeguchi A, Khawandanah M, Cherry M. Analysis of Outcome of Patients with Acute Myeloid Leukemia According to Socio-Economic Status. Blood(126):5627, 2015. e-Pub 2015.
- Cherry M, Khawandanah M, Zoe ZJ, Srour SA, Ozer H, Selby G, Ghabach B, Al-Kali A. Erlotinib is Not Effective in Patients (Pts) with JAK-2 V617F Positive Polycythemia Vera. Blood(122):1597, 2013. e-Pub 2013.
- Srour SA, Machiorlatti MG, Cherry M, Pierson N, Bhutta UZ, Thompson DM, Kurkjian CD. Acute Myeloid Leukemia: Pretreatment Biochemical and Clinical Variables Predictive For Risk Status Based On Validated Cytogenetic and Molecular Abnormalities. Blood(122):4962, 2013. e-Pub 2013.
- Srour SA, Machiorlatti M, Bhutta U, Pierson N, Cherry MA, Pant S, Thompson D, Kurkjian C. Acute Myeloid leukemia: Comparison of Epidemiology and Treatment Outcomes between Insured and Uninsured Patients. J Clin Oncol 30(15):e17012, 2012. e-Pub 2012.
- Srour SA, Cherry MA, Borders E, Parekh H, Holter JL, Herman T, Selby G. Role of Topotecan, Vinorelbine, Thiotepa, and Gemcitabine (TVTG) Chemotheapy in Relapsed/refractory Adult Acute Leukemia: A Single-Institution Retrospective Analysis. S. J Clin Oncol 29(15):S6603, 2011. e-Pub 2011.
Book Chapters
- Saengboon, S, Srour, S. Immunotherapy and hematopoietic stem cell transplantation, 115-133, 2024.
- Iyer, PC, Srour, S, Hofmann, M, Cabanillas, ME. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer, 307-324, 2024.
- Saengboon, S, Srour, S. Patient and Donor Assessments in Preparation for Transplant, 55-65, 2023.
- Srour, S, Popat, UR. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms, 279-286, 2023.
- Srour SA, Qazilbash MH. Chronic Myeloid Leukemias. In: The Bethesda Handbook of Clinical Oncology. 5. Lippincott, Williams & Wilkins, 2018.
- Srour SA, Qazilbash MH. Chronic Myeloid Leukemias. In: The Bethesda Review of Clinical Oncology. 1st, 2018.
- Srour SA, Fayad LE. Treatment of Early Stage Hodgkin Lymphoma. In: Hodgkin’s Lymphoma. Intech, 113-144, 2012.
- Srour SA, Fayad L. Treatment of Hodgkin Lymphoma. In: Neoplastic Hematopathology: Experimental and Clinical Hematopathology”. Human Press, 367-389, 2010.
Letters to the Editor
- Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
- Smallbone, PI, Sekhar, M, Srour, S, Ramdial, JL, Carmicheal Kusy, CL, Shpall, E, Popat, UR. Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis. American journal of hematology 100: 305-309, 2025.
Patient Reviews
CV information above last modified March 31, 2026